Tags Archive Navigation
icon
-
Media ReleaseNovartis delivers solid growth in second quarter and continues transformation to a focused medicines company
-
Media ReleaseNovartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer
-
Media ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media ReleaseNovartis appoints Elizabeth Barrett as Oncology Head
-
Media ReleaseNovartis ernennt Elizabeth Barrett zur Chefin Onkologie
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- › Next page